Daniel P. Petrylak, MD, Talks About Importance of Mentorships in Genitourinary Oncology

Video

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, reflects upon mentorship during his training to become an oncologist.

CancerNetwork® spoke with Daniel P. Petrylak, MD, professor of medicine (medical oncology) and of urology and co-leader of Cancer Signaling Networks at Yale Cancer Center as well as co-chair of the at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC, about and how different to field of urothelial carcinoma treatment is and how his mentor Alan Yagoda, MD, would have felt about these positive changes.

Transcript:

Dr. Jean Hoffman-Censits presented a case [during the conference about] a patient who has been alive several years and has received [most] forms of therapy, including chemotherapy, immunotherapy, and targeted treatments. We commented in the session that [had this been 5 years ago], the patient wouldn’t be alive today. This is one of the most exciting times for the treatment of urothelial carcinoma. I only wish that Alan Yagoda, MD, who was my mentor in this field, was still alive today. He was one of the inventors of the MVAC [methotrexate, vinblastine sulfate, doxorubicin hydrochloride, and cisplatin] regimen. At that point, that was one of the groundbreaking treatments for metastatic urothelial cancer. [There was a gap in progress] for a number of years, where we didn’t have anything that worked in the second line. Unfortunately, he can’t see today what’s going on and all the different progress that has been made, especially in the last 5 years.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content